NEW YORK (GenomeWeb News) – A clinical study targeting dysferlinopathy expected to cost $3 million has exceeded its patient recruitment goal, the Jain Foundation, which is funding the study, said today.

The Clinical Outcome Study for Dysferlinopathy has recruited 193 patients, passing the original goal of 150. The three-year project is being conducted in 14 centers and is led by Kate Bushby at Newcastle University and Laura Rufibach at the Jain Foundation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.